GEN Exclusives

More »

GEN News Highlights

More »
Aug 27, 2009

Abbott to Develop Molecular Companion Diagnostic for Pfizer’s NSCLC Drug Candidate

  • Abbott has agreed to develop a molecular companion test for one of Pfizer’s investigational drugs for the treatment of non-small-cell lung cancer (NSCLC) called PF-02341066. The compound reportedly targets certain genes that have been implication in the progression of non-small-cell lung cancer (NSCLC).

    “Pfizer's novel compound for treating non-small-cell lung cancer appears to be ideally suited to individualized therapy,” according to Stafford O'Kelly, head of Abbott's molecular diagnostics business.

    To be eligible to receive Pfizer's oral therapy, a particular genetic translocation, or rearrangement, known to be found in NSCLC tumors and other cancers but not in normal cells, must be present. Abbott will develop a test to determine a patient's genetic status, and it will be used in patient selection for future clinical trials.

    “This test will allow us to focus on the patient population most likely to benefit from our NSCLC candidate,” points out Garry Nicholson, GM, Pfizer oncology business unit.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?